Suzhou Basecare Medical (HKG:2170) saw its shares surge by nearly 10% on Wednesday after the company announced that it has obtained approval for the renewal of the registration certificate for its PGT-A kit from China's National Medical Products Administration.
The PGT-A kit is used for accurately detecting DNA abnormalities in embryos, and the renewed registration certificate is valid until February 20, 2030.
The positive regulatory development for one of the company's key products was welcomed by investors, driving the stock price higher on Wednesday.